

**Faron Pharmaceuticals Oy**

("Faron" or "the Company")

**Exercise of options****Issue of equity**

*Company announcement, June 12, 2023*

**TURKU, FINLAND / BOSTON, MA** – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, announces that it has received notifications from option holders to exercise 2015D options over 57,000 shares in the Company at an exercise price of EUR 1.09 per share and 2015B options over 5,172 shares in the Company at an exercise price of EUR 2.90 per share under the Company's 2015 Option Plan ("New Ordinary Shares"). The terms and conditions of the 2015 Option Plan are available on the Company's website at [https://www.faron.com/sites/default/files/Option%20Plan%202015\\_Terms%20and%20Conditions\\_20200518.pdf](https://www.faron.com/sites/default/files/Option%20Plan%202015_Terms%20and%20Conditions_20200518.pdf).

Applications will be made to the London Stock Exchange and Nasdaq Helsinki to admit the New Ordinary Shares to trading on AIM and Nasdaq First North Growth Market, respectively. Admission of the New Ordinary Shares is expected to occur on or around June 14, 2023 following issue and registration of the new Ordinary Shares on or around June 13, 2023 ("Registration"). The New Ordinary Shares will rank *pari passu* with existing ordinary shares.

Faron's enlarged issued number of shares immediately following Registration will be 63,559,863 ordinary shares with voting rights attached. The Company has no shares in treasury; therefore upon, and subject to, Registration, the total number of voting rights in Faron will be 63,559,863. This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the issued shares and votes of the Company.

**For more information please contact:****Investor contacts:****US, Faron Pharmaceuticals**

Julia Balanova

VP, Investor Relations

[julia.balanova@faron.com](mailto:julia.balanova@faron.com)

Phone: +1 (917) 306-6096

**EUR, Faron Pharmaceuticals**

Yrjö Wichmann  
VP, Investor Relations  
[yrjo.wichmann@faron.com](mailto:yrjo.wichmann@faron.com)  
Phone: +358 (0)40 5868 979

**Media Contact**

**Faron Pharmaceuticals**  
Jennifer C. Smith-Parker  
Head of Communications  
[Jennifer.Smith-Parker@faron.com](mailto:Jennifer.Smith-Parker@faron.com)

**Cairn Financial Advisers LLP, Nomad**

Sandy Jamieson, Jo Turner  
Phone: +44 (0) 207 213 0880

**Peel Hunt LLP, Broker**

Christopher Golden, James Steel  
Phone: +44 (0) 20 7418 8900

**Sisu Partners Oy, Certified Adviser on Nasdaq First North**

Juha Karttunen  
Phone: +358 (0)40 555 4727  
Jukka Järvelä  
Phone: +358 (0)50 553 8990

**Consilium Strategic Communications**

David Daley, Lindsey Neville  
[faron@consilium-comms.com](mailto:faron@consilium-comms.com)  
Phone: +44 (0)20 3709 5700

**About Faron Pharmaceuticals Oy**

Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), together with its subsidiaries, is a clinical stage biopharmaceutical group focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer. *Bexmarilimab*, a novel anti-Clever-1 humanized antibody, is its investigational immunotherapy with the potential to remove immunosuppression of cancers through targeting myeloid cell function. *Bexmarilimab* is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments including immune checkpoint molecules, and as a monotherapy for untreatable solid tumors. Faron is headquartered in Turku, Finland. Further information is available at [www.faron.com](http://www.faron.com).